Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

  • Showing results for a modified search because your search retrieved no results.
2.

Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.

Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A.

J Biol Chem. 2002 May 3;277(18):15712-20. Epub 2002 Feb 28.

3.

Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.

Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E.

PLoS One. 2013;8(2):e57289. doi: 10.1371/journal.pone.0057289. Epub 2013 Feb 21.

4.

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.

Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS.

Oncogene. 2014 Mar 20;33(12):1590-600. doi: 10.1038/onc.2013.92. Epub 2013 Apr 1.

5.

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

Hoang B, Frost P, Shi Y, Belanger E, Benavides A, Pezeshkpour G, Cappia S, Guglielmelli T, Gera J, Lichtenstein A.

Blood. 2010 Nov 25;116(22):4560-8. doi: 10.1182/blood-2010-05-285726. Epub 2010 Aug 4.

6.

Comparative effects of PP242 and rapamycin on mTOR signalling and NOTCH signalling in leukemia cells.

Ono A, Oike R, Okuhashi Y, Takahashi Y, Itoh M, Nara N, Tohda S.

Anticancer Res. 2013 Mar;33(3):809-13.

PMID:
23482748
7.

ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer.

Ye Q, Cai W, Zheng Y, Evers BM, She QB.

Oncogene. 2014 Apr 3;33(14):1828-39. doi: 10.1038/onc.2013.122. Epub 2013 Apr 29.

8.

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR.

Cancer Res. 2005 Aug 15;65(16):7052-8.

9.

Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.

Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA.

Oncogene. 2007 Aug 16;26(38):5606-14. Epub 2007 Mar 12.

PMID:
17353907
11.

The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.

Shi F, Yang X, Gong Y, Shi R, Yang X, Naren D, Wu J.

Anticancer Drugs. 2015 Apr;26(4):410-21. doi: 10.1097/CAD.0000000000000200.

PMID:
25535978
12.

PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway.

Xing X, Zhang L, Wen X, Wang X, Cheng X, Du H, Hu Y, Li L, Dong B, Li Z, Ji J.

Anticancer Drugs. 2014 Nov;25(10):1129-40. doi: 10.1097/CAD.0000000000000148.

13.

The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.

Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.

Invest Ophthalmol Vis Sci. 2010 Jan;51(1):421-9. doi: 10.1167/iovs.09-3974. Epub 2009 Aug 6.

PMID:
19661225
14.

A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.

Huang Y, Xi Q, Chen Y, Wang J, Peng P, Xia S, Yu S.

Anticancer Drugs. 2013 Oct;24(9):889-98. doi: 10.1097/CAD.0b013e328363c64e.

PMID:
23838676
15.

Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.

Jhanwar-Uniyal M, Gillick JL, Neil J, Tobias M, Thwing ZE, Murali R.

Adv Biol Regul. 2015 Jan;57:64-74. doi: 10.1016/j.jbior.2014.09.004. Epub 2014 Sep 18.

PMID:
25442674
17.

The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.

Zhang X, Wang X, Qin L, Xu T, Zhu Z, Zhong S, Zhang M, Shen Z.

Urology. 2015 Jan;85(1):273.e1-7. doi: 10.1016/j.urology.2014.09.020. Epub 2014 Nov 6.

PMID:
25440763
18.

Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.

Guenther MK, Graab U, Fulda S.

Cancer Lett. 2013 Sep 1;337(2):200-9. doi: 10.1016/j.canlet.2013.05.010. Epub 2013 May 16.

PMID:
23684925
19.

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.

Barrett D, Brown VI, Grupp SA, Teachey DT.

Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000. Review.

20.

Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.

Marzec M, Liu X, Wysocka M, Rook AH, Odum N, Wasik MA.

PLoS One. 2011;6(9):e24849. doi: 10.1371/journal.pone.0024849. Epub 2011 Sep 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk